Analysts' Actions: C LEN BK DTV MAR

NEW YORK ( TheStreet) -- CHANGE IN RATINGS

Automatic Data Processing ( ADP) downgraded at UBS to Neutral from Buy, UBS said. $59 price target. Full valuation, limited near term catalysts.

Albany Molecular Research ( AMRI) upgraded to hold at TheStreet Ratings.

Approach Resources ( AREX) upgraded at JP Morgan from Neutral to Overweight, JP Morgan said. Company can grow faster than its peers and trades at a relative discount.

Anixter ( AXE) downgraded at Credit Suisse from Neutral to Underperform, Credit Suisse said. $60 price target. Company is seeing lower datacom spending and industrial growth in Europe.

BNY Mellon ( BK) rated new Buy at Citigroup. $27 price target. Valuation and expect FX litigation to dissipate some of risk premium.

Cognex ( CGNX) downgraded at Piper from Neutral to Underweight, Piper Jaffray said. $27 price target. Growth could be hurt my macro headwinds.

DirecTV ( DTV) upgraded at Hudson Square from Hold to Buy, Hudson Square said. $60 price target.

Fusion-IO ( FIO) rated new Buy at Wunderlich. $38 price target. Company can continue to grow on its own or may eventually be acquired.

Genomic Health ( GHDX) rated new Outperform at Credit Suisse. $43 price target. Company can continue to gain market share.

Impax Laboratories ( IPXL) downgraded at ThinkEquity from Buy to Hold, ThinkEquity said. Valuation call, based on a $25 price target.

Marriot International ( MAR) downgraded at KBW to Market Perform from Outperform, KBW said. $42 price target. Valuation and heightened economic concerns.

Martin Marietta ( MLM) downgraded at Keybanc from Buy to Hold, Keybanc said. Valuation call.

Myriad Genetics ( MYGN) rated new Neutral at Credit Suisse. $28 price target. Near and long term concerns overshadow underlying organic growth.

Nokia ( NOK) downgraded at BMO from Market Perform to Underperform, BMO Capital said. $2 price target. Do not expect new phones to gain much traction.

Northern Trust ( NTRS) rated new Neutral at Citigroup. $50 price target. Struggle to see upside from current price.

Paychex ( PAYX) downgraded at Citigroup to Sell from Neutral, Citigroup said. $30.50 price target. Modest growth can't support rich valuation.

Paychex downgraded at UBS to Neutral from Buy, UBS said. $35 price target. Full valuation, challenging backdrop.

State Street ( STT) rated new Buy at Citigroup. $54 price target. Valuation is compelling.

Safeway ( SWY)upgraded at BMO. $25 price target. Just for U program appears to be working with customers.

Teradata ( TDC) rated new Market Perform at BMO. $86 price target. Stock is already pricing in solid growth for the remainder of the year.

Tivo ( TIVO) upgraded at Lazard from Neutral to Buy, Lazard said. Verizon deal makes a positive settlement with Motorola more likely $14 price target.

Time Warner Cable ( TWC) upgraded at Hudson Square from Hold to Buy, Hudson Square said. $110 price target.

Vulcan Materials ( VMC) downgraded at Keybanc from Buy to Hold, Keybanc said. Estimates boosted, but the stock appears fully valued at current levels.

STOCK COMMENTS / EPS CHANGES

Citigroup ( C) target lowered at Oppenheimer to $52, Oppenheimer said. Write down of MSSB. Outperform rating.

Discover Financial Services ( DFS) numbers raised at Citigroup. Shares of DFS now seen reaching $41, Citigroup said. Estimates also increased on better credit. Neutral rating.

Lennar ( LEN) estimates, target increased at KBW. LEN estimates were raised through 2013, Keefe, Bruyette & Woods said. Company is realizing higher margins. Market Perform rating and new $31 price target.

LyondellBasell ( LYB) numbers raised at Jefferies. Shares of LYB now seen reaching $61, Jefferies said. Estimates also raised on incremental improvements. Buy rating.

Old National ( ONB) target raised at Jefferies to $13, Jefferies said. Improved commercial loan growth. Hold rating.

Patterson-UTI ( PTEN) numbers raised at Guggenheim. Shares of PTEN now seen reaching $18, according to Guggenheim. Estimates also increased, as the company is cutting capital costs. Neutral rating.

Walgreen ( WAG) added to Conviction Buy List at Goldman. Earnings growth should reaccelerate in the coming quarters. $43 price target.

>To submit a news tip, email: tips@thestreet.com.

READERS ALSO LIKE:


Follow TheStreet on Twitter and become a fan on Facebook.

This article was written by a staff member of TheStreet.

More from Stocks

North Korea, Apple, GPDR and Gap - 5 Things You Must Know

North Korea, Apple, GPDR and Gap - 5 Things You Must Know

Market Can't Handle the Wild Ride: Cramer's 'Mad Money' Recap (Thursday 5/24/18)

Market Can't Handle the Wild Ride: Cramer's 'Mad Money' Recap (Thursday 5/24/18)

Replay: Jim Cramer on North Korea, Oil Prices, Apple and Carnival Corporation

Replay: Jim Cramer on North Korea, Oil Prices, Apple and Carnival Corporation

Canopy Growth: First Cannabis Firm on the NYSE Fails to Generate Buzz

Canopy Growth: First Cannabis Firm on the NYSE Fails to Generate Buzz

Video: This Startup Connects Buyers and Sellers of Legal Marijuana

Video: This Startup Connects Buyers and Sellers of Legal Marijuana